510 related articles for article (PubMed ID: 19686383)
1. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
Gaspar PA; Bustamante ML; Silva H; Aboitiz F
J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
[TBL] [Abstract][Full Text] [Related]
2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
3. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
[TBL] [Abstract][Full Text] [Related]
5. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiologically based treatment interventions in schizophrenia.
Lewis DA; Gonzalez-Burgos G
Nat Med; 2006 Sep; 12(9):1016-22. PubMed ID: 16960576
[TBL] [Abstract][Full Text] [Related]
7. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
8. From glutamatergic dysfunction to cognitive impairment: boundaries in the therapeutic of the schizophrenia.
Gaspar PA; Bustamante ML; Rojo LE; Martinez A
Curr Pharm Biotechnol; 2012 Jun; 13(8):1543-8. PubMed ID: 22283759
[TBL] [Abstract][Full Text] [Related]
9. Glutamate as a therapeutic target in psychiatric disorders.
Javitt DC
Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
[TBL] [Abstract][Full Text] [Related]
10. The acute effects of NMDA antagonism: from the rodent to the human brain.
Gunduz-Bruce H
Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
[TBL] [Abstract][Full Text] [Related]
11. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
12. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
Enomoto T; Noda Y; Nabeshima T
Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
[TBL] [Abstract][Full Text] [Related]
13. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
[TBL] [Abstract][Full Text] [Related]
14. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
Heresco-Levy U
Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
[TBL] [Abstract][Full Text] [Related]
15. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
Labrie V; Roder JC
Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
[TBL] [Abstract][Full Text] [Related]
16. A review of NMDA receptors and the phencyclidine model of schizophrenia.
Thornberg SA; Saklad SR
Pharmacotherapy; 1996; 16(1):82-93. PubMed ID: 8700797
[TBL] [Abstract][Full Text] [Related]
17. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
Mouri A; Noda Y; Enomoto T; Nabeshima T
Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
[TBL] [Abstract][Full Text] [Related]
18. Glutamatergic aspects of schizophrenia.
Tamminga C
Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
[TBL] [Abstract][Full Text] [Related]
19. Development of the glutamate, GABA, and dopamine systems in relation to NRH-induced neurotoxicity.
Benes FM
Biol Psychiatry; 1995 Dec; 38(12):783-7. PubMed ID: 8750035
[No Abstract] [Full Text] [Related]
20. The GABA-glutamate connection in schizophrenia: which is the proximate cause?
Coyle JT
Biochem Pharmacol; 2004 Oct; 68(8):1507-14. PubMed ID: 15451393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
